Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol SLC16A1 contributors: mct - updated : 19-03-2017
HGNC name solute carrier family 16, member 1 (monocarboxylic acid transporter 1)
HGNC id 10922
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • twelve transmembrane spanning segments (12TM)
  • a cytoplasmic loop between TM6 and TM7
    • conjugated PhosphoP
    HOMOLOGY
    interspecies homolog to murine Slc16a1 (87.6pc)
    homolog to rattus Slc16a1 (86.0pc)
    Homologene
    FAMILY
  • major facilitator superfamily
  • monocarboxylate porter family
    • CATEGORY transport carrier
    SUBCELLULAR LOCALIZATION     plasma membrane
    text basolateral
    basic FUNCTION
  • H+ coupled monocarboxylate transporter 1, mediating movement of lactate and pyruvate, branched-chain oxo acids, ketone bodies acetoacetate, beta-hydroxybutyrate and acetate across the colonocytes luminal membranes
  • hypoxia stimulates lactate release and modulates monocarboxylate transporter (SLC16A1, SLC16A2, and SLC16A4) expression in human adipocytes
  • involved in lactate enter in endothelial cells, and stimulatibg an autocrine NFKB/IL8 pathway driving cell migration and tube formation
  • lactate homeostasis participates in the regulation of the Schwann cells (SCs) myelination program and reveal that similar to CNS, PNS axon-glial metabolic interactions are most likely mediated by SLC16A4, SLC16A1
  • modulates cancer cell pyruvate export and growth of tumors
  • exhibits high-affinity l-lactate transport and broad substrate recognition
  • mediate L-lactate transport, but, also transports L-5-oxoproline (L-OPro), and amino acid residues, M69 and F367, are key molecular elements for the transport of L-OPro
    • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism monocarbon , other
    signaling
    glucides
    a component
    INTERACTION
    DNA
    RNA
    small molecule
  • proton linked
    • protein
  • BSG is required for the expression of SLC16A1 and SLC16A4 in the corneal endothelium
    • cell & other
    REGULATION
    repressed by miR-124
    Other upregulated in response to increased work
    SLC16A4, SLC16A1 are regulated via expression of their chaperone, BSG
    ASSOCIATED DISORDERS
    corresponding disease(s) MCTD , HHF7
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    significantly increased in colorectal carcinomas. Gain of membrane expression directly related to the presence of vascular invasion
    tumoral     --over  
    in neoplastic lymphocytes 2)
    tumoral     --over  
    in glycolytic breast tumors, and high SLC16A1 expression predicts poor prognosis in breast cancer patients
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancerbrain 
    may be a novel therapeutic target for treatment of malignant medulloblastomas
    cancer  
    pharmacological inhibition of SLC16A1 and SLC16A4 combined with metformin treatment is a potential cancer therapy
    cancerbrainglioma/neuroblstoma
    development of therapeutic approaches targeting SLC16A1 may be a promising strategy in glioblastoma treatment
    ANIMAL & CELL MODELS